Topic: Silenor
Ambien, like the benzodiazepines, is a Schedule IV controlled substance and has some potential for addiction and abuse. You may need to slowly reduce your dose after using Ambien for a prolonged period of time to reduce withdrawl.Strengths Available: Ambien also targets ...
Somaxon Pharmaceuticals (SOMX) has finally delivered a deal on Silenor, and it is an unusual one. For a fixed fee and royalties, Somaxon has hired the OTC sales force of consumer products giant Procter & Gamble (PG) for a September launch of ...
Somaxon, Procter & Gamble agree to co-promote new insomnia drug SilenorSomaxon Pharmaceuticals Inc. will team with Procter & Gamble Co. to co-promote the insomnia treatment Silenor to thousands of doctors and pharmacies.The companies will combine sales forces to target 35,000 of the ...
Combined Sales Forces to Launch Silenor to Physicians in September Procter & Gamble to Provide Pharmacy Calls and Supplemental Managed Care Support Silenor OTC Negotiation Rights Included Conference Call Scheduled for Today at 9:00 a.m. Eastern Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced ...
On March 18, 2010, Somaxon Pharmaxeuticals (SOMX) was granted FDA approval to sell Silenor 3 and 6 mg. Silenor was tested in several Phase II and 3 phase III studies in adults and the elderly with chronic insomnia and in one other ...
Somaxon to sell 4 million shares to raise funds for marketing insomnia drug SilenorJust days after receiving Food and Drug Administration approval for Silenor, biotech company Somaxon Pharmaceuticals Inc. made plans to sell 4 million shares to fund marketing of the insomnia ...
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.. Silenor is approved for the treatment of both ...
By March 21, 2010, the U.S. Food and Drug Administration (FDA) is expected to decide on the marketing approval of Somaxon Pharmaceuticals, Inc.'s (SOMX) drug Silenor, designed for the treatment of insomnia, which is the inability of an individual to fall asleep ...
The FDA will complete its review and provide an action letter to Somaxon Pharmaceuticals (SOMX) relating to the Silenor NDA by December 4, 2009.. In the letter, the FDA denied approval for the insomnia drug Silenor in its present form since it ...
I do my best to answer readers' questions, but keep in mind that my responses to these questions are my opinions and personal speculation that I have based on my own research and DD.. An email from Citizen Chin regarding Rite Aid ...
